A question regarding the market for CV. According to The Worldometers site there are currently 2.5 million active cases in the US. Of those a little over 14,000 are severe/critical.
With the FDA seemingly unimpressed with our CD10 trial results does that potentially limit sales to S/c only?

If I’m interpreting this incorrectly (and I hope I am) please let me know.